Showing 4161-4170 of 8891 results for "".
- Annual Science of Skin Event Highlights Empowering Conversations About Chronic Diseaseshttps://practicaldermatology.com/news/annual-science-skin-event-highlights-empowering-conversations-about-chronic-diseases/2467751/Empowering conversations around chronic skin diseases is something AbbVie aims to normalize. The fourth annual Science of Skin event featured a panel of experts and patients who shared insights on managing chronic skin conditions and improving quality of life, and Practical Dermatology was there.
- GUIDE: Guselkumab Dosing Every 16 Weeks Maintains Psoriasis Controlhttps://practicaldermatology.com/news/guide-guselkumab-dosing-every-16-weeks-maintains-psoriasis-control/2467730/Results from the GUIDE clinical trial showed that an extended dosing interval of guselkumab was effective for the treatment of moderate-to-sever plaque psoriasis. "Psoriasis is a chronic, systemic immune-mediated disease, predominately characterized by skin plaques, "the researchers wrote
- Consensus Statement: New Reporting Measures Aim to Improve CSCC Researchhttps://practicaldermatology.com/news/consensus-statement-new-reporting-measures-aim-improve-cscc-research/2467669/A new consensus statement from an expert panel supports the creation of standardized guidelines for retrospective studies on cutaneous squamous cell carcinoma (CSCC). "Despite this morbidity, CSCC is excluded from national cancer registries, making it difficult to study its epidemiology a
- FDA Issues Warning to Matte Beauty Over Unapproved Chemical Peelshttps://practicaldermatology.com/news/fda-issues-warning-matte-beauty-over-unapproved-chemical-peels/2467661/The U.S. Food and Drug Administration (FDA) recently sent a warning letter to Matte Beauty, addressing what the agency described as significant regulatory violations regarding their chemical peel products. According to the July 25 letter, the products in question include “TCA 100% Skin Pe
- New Algorithm Helps Detect Aggressive Basal Cell Carcinoma for Optimal Treatmenthttps://practicaldermatology.com/news/new-algorithm-helps-detect-aggressive-basal-cell-carcinoma-optimal-treatment/2467648/An algorithm can help healthcare professionals recognize which patients have a highly aggressive form of basal cell carcinoma (BCC) of the face. These are the findings of a study conducted at the University of Gothenburg. If more BCCs are correctly identified as high-risk, the patients can direct
- European Committee Recommends Approval of Delgocitinib for CHEhttps://practicaldermatology.com/news/european-committee-recommends-approval-delgocitinib-che/2467631/The European Medicine Agency Committee for Medicinal Products for Human Use (CHMP) has “adopted a positive opinion that recommends the approval” of delgocitinib cream for the treatment of adult patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequ
- Alopecia Areata Linked to Increased Psychiatric, Autoimmune Conditionshttps://practicaldermatology.com/news/alopecia-areata-linked-increased-psychiatric-autoimmune-conditions/2467632/A new retrospective analysis indicated that patients with newly diagnosed alopecia areata (AA) tended to have higher prevalence of psychiatric and autoimmune comorbidities. Researchers for the study focused on adolescents and adults aged 12-64 years diagnosed with AA (compared to a control
- ZORYVE Cream 0.15% for AD Commercially Available This Weekhttps://practicaldermatology.com/news/zoryve-cream-015-ad-commercially-available-week/2467570/Arcutis Biotherapeutics announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild-to-moderate atopic dermatitis in adults and children down to age 6 in the United States, along with a co-promotion agreement with Kowa Pharmaceuticals America, Inc. ZORYVE is a o
- Committee Recommends Expanded Indications for Spesolimab, Targeting Generalized Pustular Psoriasishttps://practicaldermatology.com/news/spevigo-gets-expanded-indication-generalized-pustular-psoriasis-treatment-and-prevention/2467564/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval expanded indications for spesolimab (SPEVIGO®), according to a press release. A humanized selective IgG1 antibody targeting the interleu
- Cemiplimab Shows Promising Results in Refractory cSCC Patientshttps://practicaldermatology.com/news/cemiplimab-shows-promising-results-refractory-cscc-patients/2467554/New research suggests cemiplimab is safe and effective in patients with refractory locally advanced (LA) and metastatic cutaneous squamous cell carcinoma (cSCC). Researchers for the retrospective single-center Canadian study sought to characterize the real-world use of cemiplimab in pati